Trouble viewing this email? View in browser
“Fertility outcomes after hysteroscopic morcellation of intrauterine leiomyomas and polyps” by Vaishali Bhalani., Andrew Chang, Christen Adkins, Serena H. Chen, and Michael Scheiber in the Journal of Reproductive Medicine assessed the fertility outcomes in infertile women after hysteroscopic morcellation of intrauterine lesions using data from:
The MyoSure tissue removal system demonstrated real-world effectiveness for improving the success of fertility treatments by resecting intrauterine pathology and normalizing the cavity prior to ART
No intra-operative complications occurred
In women with infertility or recurrent pregnancy loss with intrauterine pathology, MyoSure hysteroscopic tissue removal for normalization of the cavity supports subsequent conception and live birth.
Get the details on the findings of the study.

The MyoSure® tissue removal system is intended for hysteroscopic intrauterine procedures by trained gynecologists to resect and remove tissue including submucous myomas, endometrial polyps, and retained products of conception. It is not appropriate for patients who are or may be pregnant, or are exhibiting pelvic infection, cervical malignancies, or previously diagnosed endometrial cancer.


REFERENCE: Vaishali Bhalani, M.D., Andrew Chang, M.D., Christen Adkins, M.D., Serena H. Chen, M.D., and Michael Scheiber, M.D., M.P.H. Fertility outcomes after hysteroscopic morcellation of intrauterine leiomyomas and polyps. J Reprod Med. 2016;61(4):327-335.

EMB-00892-001 ©2017 Hologic, Inc. Hologic, MyoSure, The Science of Sure, and associated logos are trademarks or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries.